1. Home
  2. SOAR vs DRMA Comparison

SOAR vs DRMA Comparison

Compare SOAR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Volato Group Inc.

SOAR

Volato Group Inc.

HOLD

Current Price

$0.23

Market Cap

5.3M

Sector

Finance

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.24

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOAR
DRMA
Founded
2021
2014
Country
United States
United States
Employees
N/A
9
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOAR
DRMA
Price
$0.23
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
6.2M
89.4K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
$0.28
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.59
52 Week High
$4.36
$7.33

Technical Indicators

Market Signals
Indicator
SOAR
DRMA
Relative Strength Index (RSI) 40.89 44.86
Support Level $0.20 $1.13
Resistance Level $0.35 $1.40
Average True Range (ATR) 0.04 0.09
MACD 0.00 0.00
Stochastic Oscillator 24.29 23.64

Price Performance

Historical Comparison
SOAR
DRMA

About SOAR Volato Group Inc.

Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: